Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Submits Kineret, Enbrel sBLAs; Triangle Files Coviracil NRTI

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen’s Kineret Oct. 21 sBLA for a claim to inhibit progression of structural damage in adults with moderately to severely active rheumatoid arthritis is based on a single 12-month, double-blind, placebo-controlled trial.

Related Content

Zometa two-year data "approvable"
Amgen builds structural damage claims





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts